SCHEMBL15260286

SCHEMBL15260286

CC(C)(C)OC(=O)N1CCCC1[C@H](O)c1ccc(Cl)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2R P25116 1/20 0.47
ALDH1A1 P00352 3/20 0.43
NR1H2 P55055 2/20 0.43
NR1H3 Q13133 2/20 0.43
LMNA P02545 4/20 0.41
TSHR P16473 4/20 0.41
NPSR1 Q6W5P4 2/20 0.39
OPRK1 P41145 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPT P10636 2/20 0.39
HTT P42858 2/20 0.39
MAPK1 P28482 2/20 0.39
NPC1 O15118 2/20 0.39
CHRNA3 P32297 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
APP P05067 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15260287 1.00 F2R (0.47) F2RALDH1A1NR1H2NR1H3LMNA
SCHEMBL15260288 1.00 F2R (0.47) F2RALDH1A1NR1H2NR1H3LMNA
SCHEMBL10132308 1.00 F2R (0.47) F2RALDH1A1NR1H2NR1H3LMNA
SCHEMBL10132391 0.92 F2R (0.47) F2RALDH1A1NR1H2NR1H3LMNA
SCHEMBL10132505 0.90 F2R (0.55) F2RALDH1A1LMNATSHRNPSR1
SCHEMBL10132344 0.90 NR1H2 (0.47) F2RALDH1A1NR1H2NR1H3LMNA
SCHEMBL14677740 0.88 ALDH1A1 (0.43) ALDH1A1NR1H2NR1H3LMNATSHR
SCHEMBL14677739 0.88 ALDH1A1 (0.43) ALDH1A1NR1H2NR1H3LMNATSHR
SCHEMBL14677741 0.88 ALDH1A1 (0.43) ALDH1A1NR1H2NR1H3LMNATSHR
SCHEMBL2475987 0.88 LMNA (0.47) F2RALDH1A1NR1H2NR1H3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3321262-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2021-01-13 EP disclosed
EP-3321262-A1 SERINE/THREONINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2018-05-16 EP disclosed
US-20180127393-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2018-05-10 US disclosed
US-9708290-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-07-18 US disclosed
US-20160122316-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-05-05 US disclosed
US-9259470-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2016-02-16 US disclosed
US-20140249127-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2014-09-04 US disclosed
US-8697715-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2014-04-15 US disclosed
US-20130252934-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2013-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122316-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K11, TTBK1 F2R 1592/4885ALDH1A1 3280/4885NR1H2 2750/4885
US-20140249127-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K11, TTBK1 F2R 1592/4885ALDH1A1 3280/4885NR1H2 2750/4885
US-20180127393-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K11, TTBK1 F2R 1592/4885ALDH1A1 3280/4885NR1H2 2750/4885
US-20130252934-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K11, TTBK1 F2R 1592/4885ALDH1A1 3280/4885NR1H2 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.